Stem cells have been investigated for their potential to support pancreatic function, particularly in the context of diabetes and pancreatic injury. Scientific interest in this area focuses mainly on the ability of certain types of stem cells (such as mesenchymal stem cells and induced pluripotent stem cells) to differentiate into insulin-producing beta cells, which are located in the pancreas, or to secrete factors that may aid in the repair and regeneration of pancreatic tissue. Preclinical studies in animal models have demonstrated that stem cell therapies can lead to improved glycemic control and partial recovery of pancreatic function. Some early-stage human clinical trials have also reported promising results, including increased C-peptide levels and improved insulin independence in select patients with type 1 diabetes. However, these clinical studies are generally small, preliminary, and vary in methodology, so results should be interpreted with caution. There is not yet robust, large-scale clinical evidence to definitively establish stem cell therapy as a standard treatment for pancreatic diseases, but scientific validation exists at the experimental and early clinical stages. Ongoing research aims to address safety, efficacy, and long-term outcomes. Therefore, the use of stem cells to support the pancreas is based on scientific rationale and early evidence, but widespread clinical application awaits further validation.